Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study

David Michelson, Albert J. Allen, Joan Busner, Charles Casat, David Dunn, Christopher Kratochvil, Jeffrey Newcorn, F. Randy Sallee, R. Bart Sangal, Keith Saylor, Scott West, Douglas Kelsey, Joachim Wernicke, Nancy J. Trapp, Donald Harder

Research output: Contribution to journalArticle

509 Citations (Scopus)

Abstract

Objective: The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). Method: In a double-blind study, children and adolescents with ADHD (N=171, age range=6-16 years) were randomly assigned to receive 6 weeks of treatment with either atomoxetine (administered once daily) or placebo. Results: Outcomes among atomoxetine-treated patients were superior to those of the placebo treatment group as assessed by investigator, parent, and teacher ratings. The treatment effect size (0.71) was similar to those observed in previous atomoxetine studies that used twice-daily dosing. Parent diary ratings suggested that drug-specific effects were sustained late in the day. Discontinuations due to adverse events were low (less than 3%) for both treatment groups, and no serious safety concerns were observed. Conclusions: Once-daily administration of atomoxetine is an effective treatment for children and adolescents with ADHD.

Original languageEnglish (US)
Pages (from-to)1896-1901
Number of pages6
JournalAmerican Journal of Psychiatry
Volume159
Issue number11
DOIs
StatePublished - Nov 1 2002

Fingerprint

Attention Deficit Disorder with Hyperactivity
Placebos
Therapeutics
Double-Blind Method
Atomoxetine Hydrochloride
Research Personnel
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder : A randomized, placebo-controlled study. / Michelson, David; Allen, Albert J.; Busner, Joan; Casat, Charles; Dunn, David; Kratochvil, Christopher; Newcorn, Jeffrey; Sallee, F. Randy; Sangal, R. Bart; Saylor, Keith; West, Scott; Kelsey, Douglas; Wernicke, Joachim; Trapp, Nancy J.; Harder, Donald.

In: American Journal of Psychiatry, Vol. 159, No. 11, 01.11.2002, p. 1896-1901.

Research output: Contribution to journalArticle

Michelson, D, Allen, AJ, Busner, J, Casat, C, Dunn, D, Kratochvil, C, Newcorn, J, Sallee, FR, Sangal, RB, Saylor, K, West, S, Kelsey, D, Wernicke, J, Trapp, NJ & Harder, D 2002, 'Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study', American Journal of Psychiatry, vol. 159, no. 11, pp. 1896-1901. https://doi.org/10.1176/appi.ajp.159.11.1896
Michelson, David ; Allen, Albert J. ; Busner, Joan ; Casat, Charles ; Dunn, David ; Kratochvil, Christopher ; Newcorn, Jeffrey ; Sallee, F. Randy ; Sangal, R. Bart ; Saylor, Keith ; West, Scott ; Kelsey, Douglas ; Wernicke, Joachim ; Trapp, Nancy J. ; Harder, Donald. / Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder : A randomized, placebo-controlled study. In: American Journal of Psychiatry. 2002 ; Vol. 159, No. 11. pp. 1896-1901.
@article{264f3a614f0f4624ba59e4725f03f651,
title = "Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study",
abstract = "Objective: The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). Method: In a double-blind study, children and adolescents with ADHD (N=171, age range=6-16 years) were randomly assigned to receive 6 weeks of treatment with either atomoxetine (administered once daily) or placebo. Results: Outcomes among atomoxetine-treated patients were superior to those of the placebo treatment group as assessed by investigator, parent, and teacher ratings. The treatment effect size (0.71) was similar to those observed in previous atomoxetine studies that used twice-daily dosing. Parent diary ratings suggested that drug-specific effects were sustained late in the day. Discontinuations due to adverse events were low (less than 3{\%}) for both treatment groups, and no serious safety concerns were observed. Conclusions: Once-daily administration of atomoxetine is an effective treatment for children and adolescents with ADHD.",
author = "David Michelson and Allen, {Albert J.} and Joan Busner and Charles Casat and David Dunn and Christopher Kratochvil and Jeffrey Newcorn and Sallee, {F. Randy} and Sangal, {R. Bart} and Keith Saylor and Scott West and Douglas Kelsey and Joachim Wernicke and Trapp, {Nancy J.} and Donald Harder",
year = "2002",
month = "11",
day = "1",
doi = "10.1176/appi.ajp.159.11.1896",
language = "English (US)",
volume = "159",
pages = "1896--1901",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "11",

}

TY - JOUR

T1 - Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder

T2 - A randomized, placebo-controlled study

AU - Michelson, David

AU - Allen, Albert J.

AU - Busner, Joan

AU - Casat, Charles

AU - Dunn, David

AU - Kratochvil, Christopher

AU - Newcorn, Jeffrey

AU - Sallee, F. Randy

AU - Sangal, R. Bart

AU - Saylor, Keith

AU - West, Scott

AU - Kelsey, Douglas

AU - Wernicke, Joachim

AU - Trapp, Nancy J.

AU - Harder, Donald

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Objective: The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). Method: In a double-blind study, children and adolescents with ADHD (N=171, age range=6-16 years) were randomly assigned to receive 6 weeks of treatment with either atomoxetine (administered once daily) or placebo. Results: Outcomes among atomoxetine-treated patients were superior to those of the placebo treatment group as assessed by investigator, parent, and teacher ratings. The treatment effect size (0.71) was similar to those observed in previous atomoxetine studies that used twice-daily dosing. Parent diary ratings suggested that drug-specific effects were sustained late in the day. Discontinuations due to adverse events were low (less than 3%) for both treatment groups, and no serious safety concerns were observed. Conclusions: Once-daily administration of atomoxetine is an effective treatment for children and adolescents with ADHD.

AB - Objective: The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). Method: In a double-blind study, children and adolescents with ADHD (N=171, age range=6-16 years) were randomly assigned to receive 6 weeks of treatment with either atomoxetine (administered once daily) or placebo. Results: Outcomes among atomoxetine-treated patients were superior to those of the placebo treatment group as assessed by investigator, parent, and teacher ratings. The treatment effect size (0.71) was similar to those observed in previous atomoxetine studies that used twice-daily dosing. Parent diary ratings suggested that drug-specific effects were sustained late in the day. Discontinuations due to adverse events were low (less than 3%) for both treatment groups, and no serious safety concerns were observed. Conclusions: Once-daily administration of atomoxetine is an effective treatment for children and adolescents with ADHD.

UR - http://www.scopus.com/inward/record.url?scp=0036842531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036842531&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.159.11.1896

DO - 10.1176/appi.ajp.159.11.1896

M3 - Article

C2 - 12411225

AN - SCOPUS:0036842531

VL - 159

SP - 1896

EP - 1901

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 11

ER -